Episode Details

Michael Thomas Henderson, CEO of Apogee Therapeutics, sold $1.5M worth of stock, a small fraction of his holdings. The sale was part of a pre-set plan and doesnt indicate insider doubts. Apogee, a biotech firm working on skin and lung treatments, recently raised $350M and expects positive trial results soon, positioning it well for potential approvals and partnerships.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4be454a6427219e4